Acute lung injury is less a single disease than a catastrophic ending shared by many of them. Sepsis, pneumonia, trauma and severe viral infection can all push the delicate membrane between air and blood into inflammation, leakage and failure. Intensive-care teams can support a patient while the lungs recover. They have fewer ways to reach into the cellular machinery and stop the damage itself. Peroxitech, a small Philadelphia biotechnology company born from University of Pennsylvania research, thinks it has found an unusually precise place to intervene.
Its lead candidate is PIP-2, a peptide nine amino acids long. The sequence comes from human lung surfactant protein A and travels inside liposomes. Its job is not to soak up reactive oxygen species after they appear. It is designed to inhibit one activity of peroxiredoxin 6, a protein that helps activate NOX1 and NOX2 enzymes. Those enzymes generate reactive oxygen species that can amplify inflammation and tissue injury. In plain English: Peroxitech wants to turn off the tap, not chase the water around the floor.
The idea before the company
The science began with Aron Fisher, a physician and longtime University of Pennsylvania lung researcher, and Sheldon Feinstein, a molecular biologist who spent more than three decades studying the lung. Their work focused on peroxiredoxin 6, or Prdx6, an odd-job protein with both protective and potentially damaging activities. One part helps reduce oxidized phospholipids. Another, its phospholipase A2 activity, participates in a chain that activates NOX enzymes. Block that second activity, the researchers reasoned, and the body might retain useful biology while avoiding an early burst of self-inflicted oxidative damage.
Published work in 2018 narrowed a human surfactant-protein sequence to the nine-amino-acid PIP-2. The researchers found that liposome delivery mattered in living animals and reported a tissue half-life of roughly 50 hours for the inhibitory effect. A 2019 mouse study then found lower markers of inflammation, permeability, edema and tissue oxidation after a bacterial-toxin challenge. Later mouse work in a sepsis model supported the same mechanism. Peroxitech had a candidate and, more importantly, a coherent reason for why it might work.
Where PIP-2 tries to break the chain
This is the company's cleanest distinction from conventional antioxidants. An antioxidant competes with tissue for molecules that are already reactive. PIP-2 is meant to prevent a source of those molecules from switching on. It is a more upstream thesis and therefore an appealing one. It is also a thesis that depends on the targeted pathway being important enough, early enough and consistent enough across a wildly heterogeneous patient population.
What $25 million was meant to buy
Peroxitech launched through Penn Center for Innovation's UPstart program in 2016. Thomas Han, a pharmaceutical executive with experience in operations, corporate development and commercialization, joined the two scientific founders as CEO and co-founder. The setup is familiar in biotechnology: university inventors bring a mechanism and intellectual property; an operator builds the development plan around them.
The company first lived on research support and grants. In 2020, it announced an NIH award to continue developing its acute-lung-injury compound. NIH public award tables show roughly $300,000 to Peroxitech LLC that fiscal year. In May 2021, Xontogeny supplied seed financing and an embedded development team. The announced work included pharmacokinetics, toxicology and other IND-enabling preparation - the unglamorous package required before a drug can be tested in people.
COVID made the urgency impossible to miss. Peroxitech's 2021 seed announcement foregrounded COVID-induced lung injury and described the need to move quickly. But the virus did not create the company's biology. By the $25 million Series A in December 2022, the framing had widened back to acute lung injury regardless of cause. That was a sensible change of emphasis: one mechanism, multiple triggers, and a market not tied to the fate of a single pandemic.
“The clever pivot was not a new molecule. It was returning from one headline-grabbing cause to the broader syndrome the science had targeted all along.”YesPress analysis
The Perceptive Xontogeny Venture Fund led that Series A. The stated destination was clear: build on preclinical work, complete IND-enabling studies and enter clinical development. The cash was not the cost of a finished drug. It was the price of crossing the hazardous stretch between an academic result and a credible human experiment. In January 2026, Penn listed Peroxitech among startups raising Series B capital, suggesting that the next leg still requires more money.
The pig in the room
Mouse models are useful, economical and notorious for flattering drug candidates. Peroxitech's most informative public update arrived in 2024 from a porcine study run with researchers at CBSET and collaborators connected to Penn, MIT and Brigham and Women's Hospital. Pigs received lipopolysaccharide to induce sepsis-like acute lung injury. Treated animals showed less lung injury, greater cardiovascular stability and fewer early euthanasias than untreated animals. Biomarkers in lung fluid also moved in the intended direction.
That is meaningful progress because pig anatomy and critical-care management can better approximate human physiology than a mouse experiment. It is not clinical proof. The study was preclinical, the model was controlled, and company stockholders helped design and interpret the research. Those facts do not erase the result; they define how much weight it can carry.
A separate 2024 paper explored human pulmonary endothelial cells exposed to serum from patients who died with COVID-19. Liposomal PIP-2 reduced signals of oxidative stress, inflammation and cell death in that laboratory system. Together, the papers tell a consistent story across species and experimental settings. Consistency is exactly what a preclinical company should build. Translation is the cliff immediately after it.
What failed first
The broader field's downstream cleanup strategy. Once reactive oxygen is abundant, antioxidants must compete with tissue for highly reactive molecules. Peroxitech moved the intervention upstream.
What could fail next
Timing, delivery or biology in real patients. A liposomal peptide must reach the right cells while the targeted cascade still drives enough of the syndrome to change outcomes.
Who would use it
Not consumers. The eventual users would be hospital critical-care teams treating acute lung injury, and possibly transplant teams preserving donor organs.
How it makes money
For now, it does not report product revenue. Venture capital and grants fund development; a future licensing, partnership or direct-commercialization model remains undisclosed.
A company with no ordinary customer
Peroxitech is a product company without a commercial product. Its prospective customer is a hospital, but its first gatekeepers are regulators, clinical investigators and investors. Its users would be intensivists who cannot wait days to see whether a therapy is helping. Its beneficiaries would be patients whose lung injury may have started from bacteria, a virus, aspiration, trauma or something else entirely.
That diversity creates the market opportunity and the development headache. An etiology-independent mechanism could give one drug broad relevance. Yet a clinical trial must still identify patients in whom oxidative signaling is active, choose a dosing window, work alongside ventilation and other supportive care, and produce a measurable benefit beyond shifting biomarkers. It may not work when treatment arrives after irreversible barrier damage, when another pathway dominates, when liposome delivery is inconsistent or when suppressing NOX activity carries unacceptable effects.
The company has also tested the edges of its platform. An NIH-supported program announced in 2022 proposed using its approach to protect donor lungs from oxidative damage during storage and transport. The logic is adjacent rather than random: preserve fragile tissue by limiting the same destructive cascade. Success could increase the viable organ pool. Failure could reveal that controlled organ preservation and systemic critical illness are simply too different for one intervention.
Penn spinout launches through the UPstart program.
PIP-2 is defined in published work; mouse data and NIH support build the case.
Xontogeny adds seed capital and development support.
A donor-lung program appears; the company closes a $25 million Series A.
Pig and human-cell studies are published; Penn lists Peroxitech as raising Series B.
The useful part to steal
Biotech founders cannot copy Peroxitech's molecule. They can copy its sequence of decisions. The company began with a narrow mechanistic claim, made the smallest useful therapeutic, gathered evidence in more than one injury model, and brought in a partner built to turn university science into a development program. It used a moment of intense COVID attention without abandoning the broader biology. Then it widened into organ preservation only along the same oxidative-injury axis.
The Peroxitech playbook, minus the lab coat
- Name the upstream bottleneck, not merely the visible symptom.
- Design the smallest intervention that can test the thesis.
- Use progressively harsher models before paying for the next financing step.
- Recruit operational expertise before the science becomes a regulatory project.
- Expand only into adjacencies governed by the same mechanism.
The playbook breaks when the mechanism is elegant but minor, when the model exaggerates relevance, or when the product cannot be manufactured and delivered reliably. It also breaks if a tiny team treats external partners as substitutes for internal judgment. Peroxitech's culture, to the extent public materials reveal it, is built around collaboration: Penn science, NIH support, Xontogeny development help and specialist preclinical work. That can be capital-efficient. It can also make coordination a core competency rather than an administrative detail.
The honest verdict is neither miracle nor mirage. Peroxitech has assembled a biologically specific thesis, peer-reviewed preclinical evidence and serious financial backing around a peptide small enough to sound like a trivia answer. It has not publicly crossed the boundary that matters most. If PIP-2 enters human testing, the decisive questions will be brutally practical: Is it safe? Can it reach the relevant cells? Can clinicians give it soon enough? Does blocking this pathway change how patients feel, function or survive?
Until then, Peroxitech occupies a familiar but interesting place in the market - ahead of a laboratory curiosity, behind a medicine, and expensive enough that the next experiment must say something new.
Explore Peroxitech
Company and product status reflect public information available through August 2026.